
Otsuka Reports Positive Interim Phase 3 Results for Sibeprenlimab in Adult IgA Nephropathy
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. have announced positive topline interim results from their ongoing Phase 3 clinical trial of sibeprenlimab for treating immunoglobulin A…












